Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
Ir J Med Sci
; 190(1): 403-409, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: covidwho-629552
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 19 (COVID-19), has rapidly spread since December 2019 to become the focus of healthcare systems worldwide. Its highly contagious nature and significant mortality has led to its prioritization as a public health issue. The race to prevent and treat this disease has led to "off-label" prescribing of medications such as hydroxychloroquine, azithromycin, and Kaletra (lopinavir/ritonavir). Currently, there is no robust clinical evidence for the use of these drugs in the treatment of COVID-19, with most, if not all of these medications associated with the potential for QT interval prolongation, torsades de pointes, and resultant drug-induced sudden cardiac death. The aim of this document is to help healthcare providers mitigate the potential deleterious effects of drug-induced QTc prolongation.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Síndrome de QT Prolongado
/
Torsades de Pointes
/
Azitromicina
/
Ritonavir
/
Lopinavir
/
Tratamiento Farmacológico de COVID-19
/
Hidroxicloroquina
/
Antibacterianos
Tipo de estudio:
Estudios diagnósticos
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Humanos
Idioma:
Inglés
Revista:
Ir J Med Sci
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
S11845-020-02291-7
Similares
MEDLINE
...
LILACS
LIS